Skip to search formSkip to main contentSkip to account menu

riociguat 0.5 MG Oral Tablet

Known as: RIOCIGUAT 0.5MG TAB, RIOCIGUAT 0.5MG TAB,UD [VA Product], RIOCIGUAT 0.5MG TAB UD 
National Institutes of Health

Related topics

Related topics

4 relations
Guanylate Cyclase Stimulators [MoA]Hypertensive diseaseOral Tabletriociguat

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
The sGC-stimulator Riociguat for the treatment of Raynaud's phenomenon: A single-dose, double-blind, randomized, placebo-controlled cross-over study (DIGIT)
Background Raynaud’s phenomenon (RP) is a coldor stress-triggered digital ischemia caused by vasoconstriction in the digital… 
2015
2015
РИОЦИГУАТ – ПЕРВЫЙ ЛЕКАРСТВЕННЫЙ ПРЕПАРАТ ИННОВАЦИОННОГО КЛАССА СТИМУЛЯТОРОВ ГУАНИЛАТЦИКЛАЗЫ ДЛЯ ЛЕЧЕНИЯ БОЛЬНЫХ ЛЕГОЧНОЙ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИЕЙ
Summary Pulmonary arterial hypertension (PAH) drug therapy including prostanoids, endothelin receptor antagonists, type 5… 
2013
2013
Neuer Weg zur Therapie der pulmonalen Hypertonie?
Für die Therapie der pulmonalen Hypertonie (PH) steht mit den löslichen Guanylatcyclase-Stimulatoren eine neue Gruppe von… 
2013
2013
Riociguat zur Therapie der inoperablen chronisch thromboembolischen pulmonalen Hypertonie: Eine randomisierte, doppelblinde, placebokontrollierte Phase-III-Studie (CHEST-1)
Institute 1 Med. Klinik II, Innere Medizin, Universitätsklinikum Gießen und Marburg, Gießen 2 Med. Klinik IV und V, Innere… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)